Redeye is reviewing Genovis’s numbers with a positive bias following today’s Q1’20 results release, but note that the company has separately announced the fulfillment of the planned acquisition of US company QED Bioscience, helping the stock stage a strong rally late in the session. While we are positive to the Genovis case as revealed by our initial take on today’s results (see separate comment), and to this acquisition, we stress that little or no news was conveyed on the matter this afternoon, in our view. The move and the details conveyed are all in line and already reflected in our models and estimates.